We are pleased to share a video presentation by Prof. Em Johan Vansteenkiste (University Hospitals Leuven, Belgium), the principal investigator of our clinical trial PDC-LUNG-101 with PDC*lung01, our...

PDC*line Pharma is thrilled to announce that the primary clinical analysis results from our Phase I/II trial (PDC-LUNG-101) will be presented as a mini oral presentation at the European Society for...

We are thrilled to announce that we have been selected for an oral presentation at the “Educational Days” of the Francophone Society of Histocompatibility and Immunogenetics (SFHI), held in Strasbourg...

We are delighted to announce that we have been selected for an oral presentation at the International Session of the 50th Annual Meeting of Korean Cancer Association (KCA 2024)! PDC*line Pharma...

We are delighted to announce that we have been selected for an oral presentation at the 37th European Immunogenetics and Histocompatibility (EFI) Conference! 
The presentation has been made May 21th by...

PDC*line Pharma will be presenting a poster at the 2022 European Society for Medical Oncology I-O (ESMO Immuno-Oncology) Annual Congress taking place from 7 to 9 December 2022, in Geneva, Switzerland...

We are delighted to announce that our CEO Eric Halioua will make a company presentation and will be panelist at the Finance and Investment track organized by Festival of Biologics in Basel on November...

We are thrilled to announce that PDC*line Pharma will be presenting a poster at the ESMO - European Society for Medical Oncology Annual Meeting 2022 taking place from 9 to 13 September 2022, in Paris...

Very are delighted to announce that our CEO Eric Halioua will chair a panel April 28th at the 5th Neoantigen Summit Europe organized by Hanso Wade in Amsterdam, Netherlands from April 26th to April...

It has been a pleasure and an honor for our CEO Eric Halioua to participate Friday October 8th as a speaker at the EU-Korea Global Vaccine partnership roundtable with Mr Han-koo Yeo, Minister for...